CJC-1295 With DAC
Well StudiedGHRH analog with DAC
CJC-1295 with DAC (Mod GRF 1-29 DAC) is a synthetic GHRH analog modified with a Drug Affinity Complex (DAC) to extend its half-life. It has been studied in endocrinology research for its sustained effects on growth hormone release through GHRH receptor activation. Published research has examined its pharmacokinetics and prolonged activity profile. RaysunPeptide supplies CJC-1295 with DAC for qualified research and laboratory applications.
Mechanism of Action
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative Anti-Aging | 1mg | Once weekly | SubQ |
| Standard Protocol | 2mg | Once weekly | SubQ |
| Split Dosing | 1mg | Twice weekly (Mon/Thu) | SubQ |
| Loading Protocol | 2mg first week, then 1mg | Weekly | SubQ |
Research Indications
Growth Hormone
Continuous growth hormone release for 6-8 days per injection.
Significantly elevates IGF-1 levels for extended periods.
Weekly dosing ideal for simple administration.
Body Composition
Continuous GH elevation promotes lipolysis and fat metabolism.
Sustained anabolic environment supports muscle protein synthesis.
Anti-Aging
Accelerated healing and recovery from exercise or injury.
Peptide Interactions
Continuous GH elevation may reduce synergistic benefits of pulsatile protocols.
GHRP pulse effects diminished with continuous GH elevation.
Never combine different variants; choose based on desired release pattern.
Both provide continuous GH elevation; combination risks excessive levels.
Both are GHRH analogs; no additional benefit and potential receptor competition.
Defeats purpose and may suppress natural production.
CJC-1295 DAC is already more potent and long-lasting.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Water retention
- •Joint pain
- •Carpal tunnel symptoms
Stop Signs (Seek Medical Attention)
- ⚠Severe joint pain or carpal tunnel syndrome
- ⚠Excessive water retention affecting daily life
- ⚠Numbness or tingling in extremities
- ⚠Significant blood glucose dysregulation
- ⚠Signs of acromegaly (jaw growth, hand/feet enlargement)
- ⚠Persistent lethargy indicating adrenal effects
Contraindications
- ✕Diabetes history
- ✕Cancer history
- ✕Predisposed sleep apnea
Quality Checklist
Good Signs ✓
- High purity requirement (>98%); impurities cause more side effects
- Proper DAC labeling; legitimate products clearly state 'with DAC'
Warning Signs !
- Higher cost than non-DAC (2-3x more due to complex manufacturing)
- Foaming during mixing is normal for DAC peptides; wait for foam to settle
Bad Signs ✕
- Extremely cheap pricing (if priced similar to non-DAC, likely mislabeled)
- Clear solution immediately (should be slightly cloudy initially)
References
Subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Half-life of ~8 days. Cumulative effect after multiple doses with well-preserved GH pulsatility.
View on PubMed →Basal (trough) GH levels increased 7.5-fold. Mean GH levels increased 46% and IGF-1 levels increased 45%. Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation.
View on PubMed →Identified CJC-1295 as a long-acting GHRH analog through albumin bioconjugation (DAC technology). Binds covalently to endogenous albumin, extending half-life from minutes to days.
View on PubMed →Long-acting GHRH stimulation via CJC-1295 produces measurable changes in serum protein profiles reflecting sustained GH/IGF-1 axis activation.
View on PubMed →FAQs
How much more expensive is CJC-1295 with DAC compared to without DAC?
CJC-1295 with DAC typically costs 2-3x more than the non-DAC version due to complex albumin-binding manufacturing. The higher cost reflects the DAC technology enabling weekly dosing versus daily injections required for the basic version, making weekly administration more convenient despite the price premium.
Is CJC-1295 with DAC safe to combine with testosterone therapy?
CJC-1295 with DAC can be used with testosterone but requires careful monitoring. Combining continuous GH elevation with exogenous testosterone increases risk of joint pain, water retention, and elevated IGF-1 beyond safe levels. Most protocols separate them or use lower doses of each when combined.
Why does some people report joint pain during CJC-1295 DAC use?
Joint pain and carpal tunnel symptoms occur due to sustained GH and IGF-1 elevation causing water retention in joints and connective tissues. Unlike pulsatile protocols where GH spikes then drops, the 6-8 day DAC half-life creates continuous elevation that may stress joints, particularly in high-dose users.
Can you switch between CJC-1295 with DAC and without DAC during a cycle?
Switching between variants mid-cycle is not recommended because they have different pharmacokinetics—DAC provides sustained elevation while non-DAC creates pulsatile release. Combining them risks excessive GH levels and unpredictable effects. Choose one variant at the start and maintain consistency throughout your cycle.
